Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.60 |
| ▸ | CETP | P11597 | 1/20 | 0.45 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15034539 | 0.93 | GRM5 (0.51) | GRM5CETPLMNA | |
| SCHEMBL15034542 | 0.92 | GRM5 (0.61) | GRM5SLC6A7KDM4EL3MBTL1SCN9A | |
| SCHEMBL15034534 | 0.91 | GRM5 (0.59) | GRM5KDM4EALDH1A1 | |
| SCHEMBL15034510 | 0.89 | GRM5 (0.60) | GRM5SLC6A7KDM4EPTGS1PTGS2 | |
| SCHEMBL15034517 | 0.88 | GRM5 (0.58) | GRM5SLC6A7KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL15034536 | 0.87 | GRM5 (0.54) | GRM5SLC6A7KDM4ELMNA | |
| SCHEMBL15034561 | 0.85 | GRM5 (0.67) | GRM5KDM4ELMNA | |
| SCHEMBL15034538 | 0.85 | GRM5 (0.55) | GRM5CETPL3MBTL1ALDH1A1 | |
| SCHEMBL15034545 | 0.84 | GRM5 (0.53) | GRM5LMNA | |
| SCHEMBL15034523 | 0.84 | GRM5 (0.53) | GRM5SLC6A7L3MBTL1ALDH1A1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937176-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937176-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-20130158038-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158038-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158038-A1 | NOVEL COMPOUNDS | GRM5, GRIN1, GRM1 | GRM5 1/4885CETP 2712/4885SLC6A7 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.